Figure 2.

Experimental design. The mice were randomly divided into five groups: normal control , normal mice with Lenti-Orai1 interferenced (NLI), mice with allergic rhinitis (AR), AR mice with lenti-GFP interferenced (AR-GFP), and AR mice with lenti-Orai1 interferenced (AR-LI). The mice of AR, AR-GFP and AR-LI groups received ovalbumin (OVA)/aluminum hydroxide introperitoneal injection as sensitization on day 1, 8 and 15, followed with OVA intronasal challenges on day 22-29. The mice in group NLI and AR-LI were given the single dose of lenti-Orai1 on day 19; meanwhile, mice in group AR-GFP were given a single dose of lenti-GFP.